Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Free Cash Flow: 2019-2025

Historic Free Cash Flow for Keros Therapeutics (KROS) over the last 7 years, with Sep 2025 value amounting to $3.1 million.

  • Keros Therapeutics' Free Cash Flow rose 110.09% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.1 million, marking a year-over-year increase of 161.11%. This contributed to the annual value of -$162.8 million for FY2024, which is 28.22% down from last year.
  • According to the latest figures from Q3 2025, Keros Therapeutics' Free Cash Flow is $3.1 million, which was up 110.27% from -$30.3 million recorded in Q2 2025.
  • Over the past 5 years, Keros Therapeutics' Free Cash Flow peaked at $160.6 million during Q1 2025, and registered a low of -$46.3 million during Q4 2024.
  • For the 3-year period, Keros Therapeutics' Free Cash Flow averaged around -$14.2 million, with its median value being -$31.1 million (2023).
  • As far as peak fluctuations go, Keros Therapeutics' Free Cash Flow plummeted by 2,142.50% in 2023, and later soared by 452.93% in 2025.
  • Quarterly analysis of 5 years shows Keros Therapeutics' Free Cash Flow stood at -$19.7 million in 2021, then fell by 10.49% to -$21.8 million in 2022, then declined by 19.30% to -$26.0 million in 2023, then plummeted by 78.07% to -$46.3 million in 2024, then soared by 110.09% to $3.1 million in 2025.
  • Its last three reported values are $3.1 million in Q3 2025, -$30.3 million for Q2 2025, and $160.6 million during Q1 2025.